文章摘要

莫沙必利联合地衣芽孢杆菌治疗便秘型肠易激综合征的效果及安全性

作者: 1李雪, 1邵长江, 1王淑芳
1 连云港市第二人民医院消化内科,江苏 连云港 222000
通讯: 邵长江 Email: changjiang712@qq.com
DOI: 10.3978/j.issn.2095-6959.2022.11.023

摘要

目的:探讨莫沙必利联合地衣芽孢杆菌治疗便秘型肠易激综合征(constipation irritable bowel syndrome,IBS-C)患者的临床效果及安全性。方法:选取2017年1月至2021年12月连云港市第二人民医院收治的IBS-C患者共计126例,根据治疗方法的不同分成观察组(n=93)与对照组(n=33)。对照组给予莫沙必利治疗,观察组给予莫沙必利联合地衣芽孢杆菌治疗,比较两组临床疗效、肠道菌群及安全性。结果:观察组总有效率为89.25%,显著高于对照组的72.73%,差异有统计学意义(P<0.05);两组治疗后肠杆菌较治疗前降低、乳杆菌较治疗前增高(P<0.05),且观察组肠杆菌低于对照组,乳杆菌高于对照组(P0.05),治疗后观察组主排便频率、排便困难程度、腹胀腹痛、排便不尽均优于对照组(均P<0.05);治疗后观察组肛管静息压、最大缩榨压显著高于对照组,直肠感知域值、直肠最大耐受量、直肠肛门抑制反射均显著低于对照组(均P0.05)。结论:IBS-C患者给予莫沙必利联合地衣芽孢杆菌治疗,能够提高临床疗效,改善临床症状及肛管直肠动力指标,调节肠道菌群,且安全性较高,值得临床推广。
关键词: 莫沙必利;地衣芽孢杆菌;便秘型肠易激综合征;症状改善;安全性

Efficacy and safety of mosapride combined with Bacillus licheniformis in the treatment of constipation irritable bowel syndrome

Authors: 1LI Xue, 1SHAO Changjiang, 1WANG Shufang
1 Department of Gastroenterology, Lianyungang Second People’s Hospital, Lianyungang Jiangsu 222000, China

CorrespondingAuthor: SHAO Changjiang Email: changjiang712@qq.com

DOI: 10.3978/j.issn.2095-6959.2022.11.023

Abstract

Objective: To explore the clinical effect and safety of mosapride combined with Bacillus licheniformis in patients with constipation irritable bowel syndrome (IBS-C). Methods: A total of 126 patients with IBS-C admitted to Lianyungang Second People’s Hospital from January 2017 to December 2021 were selected and divided into an observation group (n=93) and a control group (n=33) according to different treatment methods. The control group was treated with mosapride, and the observation group was treated with mosapride combined with Bacillus licheniformis. The clinical efficacy, intestinal flora, and safety of the 2 groups were compared. Results: The total effective rate of the observation group (89.25%) was significantly higher than that of the control group (72.73%), and the difference between the 2 groups was significant (P<0.05). After the treatment, E. coli decreased and Lactobacillus increased in both groups (P<0.05), and E. coli in the observation group was lower than that in the control group and Lactobacillus was higher than that in the control group (P<0.05). Before the treatment, there was no significant difference in clinical symptoms between the 2 groups (P>0.05). After the treatment, the main defecation frequency, defecation difficulty, abdominal distension, abdominal pain, and incomplete defecation in the observation group were not all better than those in the control group (all P<0.05). After the treatment, the resting pressure and maximum compression pressure of the anal canal in the observation group were significantly higher than those in the control group, and the rectal perception range, the maximum tolerance of the rectum, and the rectal anal inhibitory reflex were significantly lower than those in the control group (all P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups (P>0.05). Conclusion: The treatment of IBS-C patients with mosapride combined with Bacillus licheniformis can improve the clinical efficacy, improve the clinical symptoms and anorectal motility index of the patients, regulate the intestinal flora of the patients, and have high safety, which is worthy of clinical promotion.

Keywords: mosapride; Bacillus licheniformis; constipation irritable bowel syndrome; symptom improvement; security

文章选项